Dose-dense paclitaxel and novel combination maintenance therapies offer survival benefits in advanced ovarian cancer
Positive results are reported from the FZOCUS-1 and ICON8B studies
How can regular exercise be integrated into the patient journey?
Although the benefits of exercise in patients with cancer are now well established, barriers to an effective integration of physical activity into cancer care remain
Novel KRAS G12C and G12D inhibitors show early signs of activity in advanced solid tumours
As it emerges from some studies presented across different cancers, toxicity remains a major challenge
How therapeutically tractable is MUC1 as a tumour-associated antigen?
Early proof-of-concept is provided showing pan-tumour activity of a novel antibody–drug conjugate
Personalised cancer vaccines: the next frontier or an elusive goal?
Although genomics-guided personalised cancer vaccines have demonstrated efficacy in early-phase clinical studies, we are still awaiting the results of larger-scale trials
How connecting the dots could deliver a breakthrough in cancer vaccines
After decades of missed promises, cancer vaccines are likely approaching prime time due to major advances in cancer immunobiology, immunotherapy and biomedical technology
Is there a role for GLP-1 in the prevention and treatment of cancer?
Interest is growing rapidly in the field of oncology in the anti-obesity drug target that has recently been investigated in large retrospective studies and preclinical models
Analysis identifies proteins VISTA and VEGF-A as prognostic of poor survival in recurrent ovarian cancer
High expression of specific immune-oncology proteins may have utility in identifying high-risk patients to inform future trial design
Is targeted therapy for PTEN-deficient metastatic hormone-sensitive prostate cancer on the horizon?
In the CAPItello281 trial, survival results with capivasertib plus abiraterone are promising, but questions remain on the accurate determination of PTEN loss in patients
Mixed results with enzalutamide in non-metastatic prostate cancer
Enzalutamide failed to deliver in high-risk localised prostate cancer, but improved survival, in combination with leuprolide, in biochemically recurrent prostate cancer